Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078048 | 1.00 | GRIK1 (0.44) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL9295 | 0.80 | GSR (0.52) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL295053 | 0.80 | GSR (0.52) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| 6-Diazo-5-Oxo-L-Norleucine SCHEMBL4281654 | 0.80 | GSR (0.52) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL3052694 | 0.77 | GSR (0.46) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| Serine SCHEMBL442652 | 0.73 | SLC1A1 (0.41) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| Serine SCHEMBL1253823 | 0.73 | SLC1A1 (0.41) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL4516176 | 0.73 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL645887 | 0.71 | ALDH1A1 (0.33) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| Azaserine SCHEMBL8861 | 0.71 | SLC1A5 (0.38) | GRIK1GRIK2GRM1GRM2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118429217-A | Unet-based multistage residual image snow removing method and Unet-based multistage residual image snow removing device | 新疆大学 | 2024-08-02 | — | — | CN | claimed |
| CN-118317773-A | Pharmaceutical composition for treating cancer | 卡尼姆生物有限公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023143608-A1 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 上海复东生物医药有限责任公司 | 2023-08-03 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023104021-A1 | METABOLIC CHECKPOINT-BASED HUMAN SERUM ALBUMIN NANO-DRUG, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳先进技术研究院 | 2023-06-15 | — | — | WO | claimed |
| CN-114306620-A | Human serum albumin nano-drug based on metabolism check point and preparation method and application thereof | 深圳先进技术研究院 | 2022-04-12 | — | — | CN | claimed |
| US-20180267067-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-09-20 | — | — | US | claimed |
| EP-3328375-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | claimed |
| EP-3328374-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | claimed |
| EP-3328827-A1 | PRODRUGS OF GLUTAMINE ANALOGS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | claimed |
| EP-3328376-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | claimed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017023791-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023793-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023787-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2016112386-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-14 | — | — | WO | claimed |
| WO-2009038289-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING FIBROSIS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-03-26 | — | — | WO | claimed |
| WO-2009038288-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CATARACT | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-03-26 | — | — | WO | claimed |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-12195419-B2 | Glutamine antagonists and uses thereof | THE JOHN HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240424004-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | BIOCANIM A S (CZ) | 2024-12-26 | — | — | US | disclosed |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240398972-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2024-12-05 | — | — | US | disclosed |
| US-20240366782-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-4433056-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | Biocanim A.s. (CZ) | 2024-09-25 | — | — | EP | disclosed |
| EP-4422695-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| US-12076412-B2 | Antibody-drug conjugates through specific linker oligopeptides | ARARIS BIOTECH AG (CH) | 2024-09-03 | — | — | US | disclosed |
| CN-118429217-A | Unet-based multistage residual image snow removing method and Unet-based multistage residual image snow removing device | 新疆大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-118317773-A | Pharmaceutical composition for treating cancer | 卡尼姆生物有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-02-08 | — | — | US | disclosed |
| CN-117350924-A | Image fusion method, device and equipment | 成都微光集电科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117333363-A | Video super-resolution method based on long-range-short range combination | 浙江大学 | 2024-01-02 | — | — | CN | disclosed |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116801910-A | Means and methods for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4232095-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20230263904-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2023143608-A1 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 上海复东生物医药有限责任公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023104021-A1 | METABOLIC CHECKPOINT-BASED HUMAN SERUM ALBUMIN NANO-DRUG, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳先进技术研究院 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023083396-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | JIHOČESKÁ UNIVERZITA V ČESKÝCH BUDEJOVICÍCH (CZ) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023072934-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| US-11572390-B2 | Chimeric insect-specific flaviviruses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-02-07 | — | — | US | disclosed |
| US-20230009398-A1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2023-01-12 | — | — | US | disclosed |
| EP-3328375-B1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | UNIV JOHNS HOPKINS (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-3692015-B1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2022-08-04 | — | — | US | disclosed |
| WO-2022084560-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| CN-114306620-A | Human serum albumin nano-drug based on metabolism check point and preparation method and application thereof | 深圳先进技术研究院 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
| CN-108135875-B | Methods and compositions for treating metabolic reprogramming disorders | 约翰霍普金斯大学 | 2021-12-31 | — | — | CN | disclosed |
| CN-108348492-B | Methods for cancer and immunotherapy using glutamine analogs | 约翰霍普金斯大学 | 2021-09-28 | — | — | CN | disclosed |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2021-05-20 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| US-10842763-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10568868-B2 | Methods and compositions for treating metabolic reprogramming disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190216757-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180267067-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
| EP-3328374-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328376-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328375-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328827-A1 | PRODRUGS OF GLUTAMINE ANALOGS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3328827-A1 | PRODRUGS OF GLUTAMINE ANALOGS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023791-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023787-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023793-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016112386-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2009038289-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING FIBROSIS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038288-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CATARACT | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-03-26 | — | — | WO | disclosed |
| US-7491410-B2 | Food grade transglutaminase inhibitor and uses thereof | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2009-02-17 | — | — | US | disclosed |
| US-20060088880-A1 | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 | MILLENNIUM PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| EP-1330166-B1 | FOOD GRADE TRANSGLUTAMINASE INHIBITOR AND USES THEREOF | TNO (NL) | 2005-08-03 | — | — | EP | disclosed |
| EP-1440165-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | MILLENNIUM PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050031603-A1 | Food grade transglutaminase inhibitor and uses thereof | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2005-02-10 | — | — | US | disclosed |
| EP-1440165-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | Millennium Pharmaceuticals, Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1330166-A1 | FOOD GRADE TRANSGLUTAMINASE INHIBITOR AND USES THEREOF | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL) | 2003-07-30 | — | — | EP | disclosed |
| US-20030124593-A1 | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 | MILLENNIUM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003038113-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2002035942-A1 | FOOD GRADE TRANSGLUTAMINASE INHIBITOR AND USES THEREOF | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2002-05-10 | — | — | WO | disclosed |
| EP-1201136-A1 | Food grade transglutaminase inhibitor and uses thereof | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL) | 2002-05-02 | — | — | EP | disclosed |
| WO-1999065516-A9 | METHODS AND COMPOSITIONS FOR TREATING DISEASES MEDIATED BY TRANSGLUTAMINASE ACTIVITY | YEDA RES & DEV (IL) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999065516-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES MEDIATED BY TRANSGLUTAMINASE ACTIVITY | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1999-12-23 | — | — | WO | disclosed |
| WO-1994005805-A1 | METHOD OF ASSAYING THE ENZYMATIC ACTIVITY OF ASPARAGINE-β-AMIDO HYDROLASES AND ASSAY KIT USEFUL IN THE METHOD | MONONEN ILKKA (FI) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994005805-A1 | METHOD OF ASSAYING THE ENZYMATIC ACTIVITY OF ASPARAGINE-β-AMIDO HYDROLASES AND ASSAY KIT USEFUL IN THE METHOD | MONONEN ILKKA (FI) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | GRIK1 1795/4885GRIK2 1848/4885GRM1 189/4885 |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | GRIK1 784/4885GRIK2 1065/4885GRM1 69/4885 |
| US-12195419-B2 | Glutamine antagonists and uses thereof | GLUL, PDCD1, CD274 | GRIK1 168/4885GRIK2 142/4885GRM1 30/4885 |
| US-20180267067-A1 | METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | GLUL, GLS, ASNS | GRIK1 144/4885GRIK2 135/4885GRM1 91/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-20240398972-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | SP1, TGM1, KDM3A | GRIK1 1048/4885GRIK2 886/4885GRM1 1287/4885 |
| US-20190216757-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | ADORA2A, ADORA1, ADORA2B | GRIK1 998/4885GRIK2 1511/4885GRM1 75/4885 |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | GRIK1 1056/4885GRIK2 1483/4885GRM1 87/4885 |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | GLS, GLS2, PC | GRIK1 256/4885GRIK2 253/4885GRM1 212/4885 |
| US-10568868-B2 | Methods and compositions for treating metabolic reprogramming disorders | GLS, GLS2, PC | GRIK1 256/4885GRIK2 253/4885GRM1 212/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | ADORA2A, ADORA1, ADORA2B | GRIK1 1056/4885GRIK2 1483/4885GRM1 87/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-20230263904-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, TGM2 | GRIK1 457/4885GRIK2 441/4885GRM1 149/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-12076412-B2 | Antibody-drug conjugates through specific linker oligopeptides | TGM1, SP1, TGM3 | GRIK1 363/4885GRIK2 381/4885GRM1 111/4885 |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-20250049943-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, PRMT3 | GRIK1 829/4885GRIK2 790/4885GRM1 434/4885 |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | GLS, GLUL, ASNS | GRIK1 314/4885GRIK2 498/4885GRM1 178/4885 |
| US-20240366782-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, PRMT3 | GRIK1 829/4885GRIK2 790/4885GRM1 434/4885 |
| US-10842763-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | GRIK1 1056/4885GRIK2 1483/4885GRM1 87/4885 |
| US-20230009398-A1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | GLUL, PDCD1, CD274 | GRIK1 167/4885GRIK2 142/4885GRM1 30/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | GRIK1 376/4885GRIK2 713/4885GRM1 32/4885 |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | ADORA2A, ADORA1, ADORA2B | GRIK1 1056/4885GRIK2 1483/4885GRM1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.